GlobeImmune Inc. (GBIM)

Overview

GlobeImmune, Inc. is a biopharmaceutical company dedicated to the development of therapeutic products for cancer and infectious diseases, leveraging its proprietary Tarmogen platform. Established in 1995 and originally known as Ceres Pharmaceuticals, Inc., the company underwent a name change to GlobeImmune, Inc. in May 2001. Headquartered in Louisville, Colorado, GlobeImmune operates as a subsidiary of ImmunityBio, Inc. The company's innovative approach and strategic collaborations with Gilead Sciences, Inc., and Celgene Corporation have positioned it as a significant player in the biopharmaceutical sector, focusing on advancing treatments through various stages of clinical trials.

Products and Services

• GS-4774

  Currently in Phase 2 clinical trials, GS-4774 is a leading product candidate developed for patients chronically infected with the hepatitis B virus (HBV), especially those undergoing oral antiviral suppressive therapy. This candidate showcases GlobeImmune's dedication to addressing viral infections with promising therapeutic options.

• GI-6301

  This candidate targets the treatment of cancers expressing the brachyury protein. GlobeImmune's efforts in developing GI-6301 reflect its commitment to fighting cancer through innovative biopharmaceutical solutions.

• GI-6207

  In Phase 2 clinical trials, GI-6207 is focused on the treatment of medullary thyroid cancer, showcasing the company's versatility in addressing a range of cancers with its proprietary technology.

• GI-4000

  Targeting resected pancreas cancer, GI-4000 is in Phase 2b clinical trials. Additionally, it is being tested for the treatment of non-small cell lung cancer and colorectal cancer in Phase 2 clinical trials, illustrating GlobeImmune's commitment to leveraging its Tarmogen platform across various forms of cancer.

• Preclinical Development Candidates

  GlobeImmune is also advancing several product candidates in preclinical development stages for a variety of infectious diseases, including GI-19000 for tuberculosis, GI-2010 for human immunodeficiency virus (HIV), and GI-18000 for hepatitis D virus infection. These endeavors demonstrate the company's broad scope in tackling infectious diseases alongside its cancer treatments.